The effects of etidronate on brain calcifications in Fahr's disease or syndrome: rationale and design of the randomised, placebo-controlled, double-blind CALCIFADE trial.
Birgitta M G SnijdersGini MathijssenMike Jl PetersMarielle H Emmelot-VonkPim A de JongSusan BakkerHeleen A CrommelinYnte M RuigrokEva H BrilstraVera Pm SchepersWilko SpieringEvelien van ValenHuiberdina L KoekPublished in: Orphanet journal of rare diseases (2024)
ClinicalTrials.gov, NCT05662111. Registered 22 December 2022, https://clinicaltrials.gov/ct2/show/NCT01585402 .
Keyphrases
- placebo controlled
- double blind
- phase iii
- phase ii
- study protocol
- clinical trial
- phase ii study
- image quality
- computed tomography
- white matter
- resting state
- dual energy
- open label
- contrast enhanced
- case report
- randomized controlled trial
- functional connectivity
- positron emission tomography
- cerebral ischemia
- magnetic resonance imaging
- multiple sclerosis
- magnetic resonance